Start New EnglishEspañol中文РусскийالعربيةTiếng ViệtFrançaisDeutsch한국어Tagalog Library Performance
BETA v.3.0

2025 ICD-10-CM code L65.1

Anagen effluvium is a disorder characterized by the premature shedding of hair shafts in the anagen, or growth, phase.It differs from telogen effluvium, where hair is shed from the resting phase.

Code L65.1 should be used when the hair loss is in the anagen or growth phase. Be sure to exclude Trichotillomania (F63.3). Use additional code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5).

Medical necessity for treatment of anagen effluvium is determined by the underlying cause.If related to a serious condition like chemotherapy or radiation, treatment is medically necessary to address the hair loss side effects and improve the patient's quality of life.If caused by a temporary exposure to toxins, the hair loss will typically resolve on its own once the exposure is removed.

Diagnosis and management of anagen effluvium falls under the purview of dermatologists, oncologists (if chemotherapy-induced), or general practitioners.Clinical responsibility includes identifying the underlying cause, providing appropriate counseling about the condition and its temporary nature, and discussing potential management strategies.

In simple words: Anagen effluvium is a type of hair loss where the actively growing hairs are shed. This often happens due to medications, especially chemotherapy, that interfere with hair growth.

Anagen effluvium is the loss of hair in the anagen or growth phase.This is often caused by medications that impair cell division, such as those used in chemotherapy. It leads to rapid hair loss, typically from the scalp, but can also affect other body hair.

Example 1: A patient undergoing chemotherapy for breast cancer experiences rapid hair loss from the scalp, eyebrows, and eyelashes. This is diagnosed as anagen effluvium., A patient with alopecia areata experiences diffuse hair loss, and during examination, exclamation point hairs, a characteristic of anagen effluvium, are noted. Further investigation reveals the patient unknowingly ingested a toxin., A patient receiving radiation therapy for a brain tumor develops localized hair loss in the area of radiation exposure. This localized hair loss is identified as anagen effluvium.

Documentation for anagen effluvium should include detailed history (including medication history, exposure to toxins, and family history of hair loss), physical exam findings (description of hair loss, presence of exclamation point hairs), and any relevant laboratory or imaging results. If associated with a medical condition, such as an autoimmune disorder or cancer treatment, it should be noted.

** Only Enterprise users with EHR integration can access case-specific answers. Click here to request access.

Discover what matters.

iFrame™ AI's knowledge is aligned with and limited to the materials uploaded by users and should not be interpreted as medical, legal, or any other form of advice by iFrame™.